Integration of miRNA profiles and clinical data for early risk assessment of bronchopulmonary dysplasia in VLBW and ELBW newborn infants: a discovery study - Scorecard - MDSpire
Advertisement
Integration of miRNA profiles and clinical data for early risk assessment of bronchopulmonary dysplasia in VLBW and ELBW newborn infants: a discovery study
Clinical Scorecard: Combining miRNA Profiles with Clinical Data for Early Risk Evaluation of Bronchopulmonary Dysplasia in Very and Extremely Low Birth Weight Infants: A Discovery Investigation
At a Glance
Category
Detail
Condition
Bronchopulmonary Dysplasia (BPD)
Key Mechanisms
miRNA expression patterns as post-transcriptional regulators of lung development
Target Population
Very and Extremely Low Birth Weight Infants (birth weight < 1,500 g)
Care Setting
Neonatal Intensive Care Unit (NICU)
Key Highlights
Identified 5 candidate miRNAs with higher levels in BPD infants.
Developed a predictive model integrating clinical data and miRNA predictors.
Achieved an adjusted LOOCV-AUC of 0.940 for early BPD risk assessment.
Guideline-Based Recommendations
Diagnosis
Use miRNA profiles in conjunction with clinical data for early BPD risk evaluation.
Management
Consider integrating miRNA biomarkers into clinical practice pending validation.
Monitoring & Follow-up
Monitor miRNA levels and clinical parameters in very low birth weight infants.
Risks
Be aware of the biological noise in blood samples that may obscure specific signals of BPD.
Patient & Prescribing Data
Preterm infants with birth weights below 1,500 g.
Current diagnostic criteria for BPD are retrospective; early prediction remains a challenge.
Clinical Best Practices
Employ correlation-based screening to mitigate biological noise in biomarker discovery.
Validate findings through external studies and RT-qPCR before clinical implementation.
